Research ExplorerPublicationsProceedings from the National Cancer Institute's Second Inte...

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies

Standard

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. / Avigan, David; Hari, Parameswaran; Battiwalla, Minoo; Bishop, Michael R; Giralt, Sergio A; Hardy, Nancy M; Kröger, Nicolaus; Wayne, Alan S; Hsu, Katharine C.

In: BIOL BLOOD MARROW TR, Vol. 19, No. 12, 01.12.2013, p. 1661-9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Avigan, D, Hari, P, Battiwalla, M, Bishop, MR, Giralt, SA, Hardy, NM, Kröger, N, Wayne, AS & Hsu, KC 2013, 'Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies', BIOL BLOOD MARROW TR, vol. 19, no. 12, pp. 1661-9. https://doi.org/10.1016/j.bbmt.2013.08.011

APA

Avigan, D., Hari, P., Battiwalla, M., Bishop, M. R., Giralt, S. A., Hardy, N. M., Kröger, N., Wayne, A. S., & Hsu, K. C. (2013). Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. BIOL BLOOD MARROW TR, 19(12), 1661-9. https://doi.org/10.1016/j.bbmt.2013.08.011

Vancouver

Avigan D, Hari P, Battiwalla M, Bishop MR, Giralt SA, Hardy NM et al. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies. BIOL BLOOD MARROW TR. 2013 Dec 1;19(12):1661-9. https://doi.org/10.1016/j.bbmt.2013.08.011

Bibtex

@article{b3cd607b9fe84c95b99bca1fd4c81603,
title = "Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies",
abstract = "In the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on Autologous Transplantation addressed the role of novel agents and immunomodulatory strategies in management of relapse after autologous hematopoietic stem cell transplantation (AHSCT). Concepts were illustrated through in-depth discussion of multiple myeloma, with broader discussion of areas relevant for relapse of other malignancies as well as in the setting of allogeneic transplantation. Dr. Hari provided an overview of the epidemiology of relapse after AHSCT in multiple myeloma, addressing clinical patterns, management implications, and treatment options at relapse, highlighting the implications of novel therapeutic agents in initial, maintenance, and relapse treatment. Dr. Avigan discussed current concepts in tumor vaccine design, including whole cell and antigen-specific strategies, use of an AHSCT platform to reverse tumor-associated immunosuppression and tolerance, and combining vaccines with immunomodulatory agents to promote establishment of durable antitumor immunity. Dr. Hsu reviewed the immunogenetics of natural killer (NK) cells and general NK biology, the clinical importance of autologous NK activity (eg, lymphoma and neuroblastoma), the impact of existing therapies on promotion of NK cell activity (eg, immunomodulatory drugs, monoclonal antibodies), and strategies for enhancing autologous and allogeneic NK cell effects through NK cell gene profiling.",
keywords = "Hematopoietic Stem Cell Transplantation, Humans, Immunomodulation, Multiple Myeloma, National Cancer Institute (U.S.), Neoplasm Recurrence, Local, Transplantation Conditioning, Transplantation Immunology, Transplantation, Autologous, United States",
author = "David Avigan and Parameswaran Hari and Minoo Battiwalla and Bishop, {Michael R} and Giralt, {Sergio A} and Hardy, {Nancy M} and Nicolaus Kr{\"o}ger and Wayne, {Alan S} and Hsu, {Katharine C}",
note = "Published by Elsevier Inc.",
year = "2013",
month = dec,
day = "1",
doi = "10.1016/j.bbmt.2013.08.011",
language = "English",
volume = "19",
pages = "1661--9",
journal = "BIOL BLOOD MARROW TR",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "12",

}

RIS

TY - JOUR

T1 - Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies

AU - Avigan, David

AU - Hari, Parameswaran

AU - Battiwalla, Minoo

AU - Bishop, Michael R

AU - Giralt, Sergio A

AU - Hardy, Nancy M

AU - Kröger, Nicolaus

AU - Wayne, Alan S

AU - Hsu, Katharine C

N1 - Published by Elsevier Inc.

PY - 2013/12/1

Y1 - 2013/12/1

N2 - In the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on Autologous Transplantation addressed the role of novel agents and immunomodulatory strategies in management of relapse after autologous hematopoietic stem cell transplantation (AHSCT). Concepts were illustrated through in-depth discussion of multiple myeloma, with broader discussion of areas relevant for relapse of other malignancies as well as in the setting of allogeneic transplantation. Dr. Hari provided an overview of the epidemiology of relapse after AHSCT in multiple myeloma, addressing clinical patterns, management implications, and treatment options at relapse, highlighting the implications of novel therapeutic agents in initial, maintenance, and relapse treatment. Dr. Avigan discussed current concepts in tumor vaccine design, including whole cell and antigen-specific strategies, use of an AHSCT platform to reverse tumor-associated immunosuppression and tolerance, and combining vaccines with immunomodulatory agents to promote establishment of durable antitumor immunity. Dr. Hsu reviewed the immunogenetics of natural killer (NK) cells and general NK biology, the clinical importance of autologous NK activity (eg, lymphoma and neuroblastoma), the impact of existing therapies on promotion of NK cell activity (eg, immunomodulatory drugs, monoclonal antibodies), and strategies for enhancing autologous and allogeneic NK cell effects through NK cell gene profiling.

AB - In the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, the Scientific/Educational Session on Autologous Transplantation addressed the role of novel agents and immunomodulatory strategies in management of relapse after autologous hematopoietic stem cell transplantation (AHSCT). Concepts were illustrated through in-depth discussion of multiple myeloma, with broader discussion of areas relevant for relapse of other malignancies as well as in the setting of allogeneic transplantation. Dr. Hari provided an overview of the epidemiology of relapse after AHSCT in multiple myeloma, addressing clinical patterns, management implications, and treatment options at relapse, highlighting the implications of novel therapeutic agents in initial, maintenance, and relapse treatment. Dr. Avigan discussed current concepts in tumor vaccine design, including whole cell and antigen-specific strategies, use of an AHSCT platform to reverse tumor-associated immunosuppression and tolerance, and combining vaccines with immunomodulatory agents to promote establishment of durable antitumor immunity. Dr. Hsu reviewed the immunogenetics of natural killer (NK) cells and general NK biology, the clinical importance of autologous NK activity (eg, lymphoma and neuroblastoma), the impact of existing therapies on promotion of NK cell activity (eg, immunomodulatory drugs, monoclonal antibodies), and strategies for enhancing autologous and allogeneic NK cell effects through NK cell gene profiling.

KW - Hematopoietic Stem Cell Transplantation

KW - Humans

KW - Immunomodulation

KW - Multiple Myeloma

KW - National Cancer Institute (U.S.)

KW - Neoplasm Recurrence, Local

KW - Transplantation Conditioning

KW - Transplantation Immunology

KW - Transplantation, Autologous

KW - United States

U2 - 10.1016/j.bbmt.2013.08.011

DO - 10.1016/j.bbmt.2013.08.011

M3 - SCORING: Journal article

C2 - 24018393

VL - 19

SP - 1661

EP - 1669

JO - BIOL BLOOD MARROW TR

JF - BIOL BLOOD MARROW TR

SN - 1083-8791

IS - 12

ER -